Alkem Laboratories Limited announced the launch of semaglutide in single-shot pre-filled syringes at a price starting INR350, becoming the first company in India to offer this delivery format. The company received approval from the Drugs Controller General of India (DCGI) to manufacture and market the product for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise. This launch aims to lower entry barriers to treatment by offering an affordable, ready-to-use option that enhances access and convenience for patients.

In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens. The company has also received regulatory approval for semaglutide vials, which are expected to be launched soon. Dr. Vikas Gupta, Chief Executive Officer of Alkem, stated that the introduction of pre-filled syringes widens the choice available to doctors and patients alongside the existing pen options, addressing the continuous rise in disease burden in India.

Operational Context

The introduction of the single-shot pre-filled syringe format complements the company's existing portfolio of injection pens. By offering multiple, practical drug delivery formats, Alkem intends to help more patients initiate and adhere to therapy. The company remains committed to advancing high-quality, affordable medicines across key therapeutic areas to support better patient care in India.

Alkem Laboratories Limited reported a consolidated net profit of ₹23,018 million for the financial year ended March 31, 2026, representing a 6.3% increase from the prior year. The company achieved its highest ever EBITDA of ₹30,052 million, an increase of 19.6% year-on-year, with an EBITDA margin of 20.4%. Revenue from operations for FY26 stood at ₹147,123 million, growing 13.5% compared to FY25. The board has recommended a final dividend of ₹10 per equity share, pending shareholder approval.

For the quarter ended March 31, 2026, the company recorded a consolidated net profit of ₹2,365 million, a decline of 22.7% from ₹3,059 million in the corresponding quarter of the previous year. Revenue from operations for Q4FY26 was ₹36,033 million, up 14.6% year-on-year. The decline in quarterly profit was attributed to exceptional items totaling ₹1,350 million, including a ₹747 million impairment of real estate investments and an incremental liability of ₹602.7 million towards gratuity and leave encashment costs following the finalisation of Central Rules under the Labour Codes. The Audit Committee reviewed the results on May 27, 2026, and the Board approved them on May 28, 2026.

Analyst View: Nomura Maintains Buy

Nomura Holdings has maintained its Buy rating on Alkem Laboratories with a target price of ₹6,890. The brokerage noted that Q4 revenue was in line with estimates, while EBITDA beat expectations by 11%, driven by strong gross margin expansion to 65.4% (+606bps YoY). However, PAT was impacted by one-off exceptional losses of ₹1.35bn related to real estate impairment and labour code changes, along with a higher tax rate. Nomura noted that FY27 guidance was in line to ahead of expectations. The stock currently trades at 23.6x/19.7x FY27F/FY28F adjusted EPS.

Consolidated Financial Results for FY26

The following table presents the consolidated financial performance for the full year:

Standalone Financial Results for FY26

On a standalone basis, the company's financial results for the full year are as follows:

Operational Highlights

Domestic business revenue grew 9.7% year-on-year to ₹98,514 million, while international business revenue increased 22.5% to ₹46,810 million. The US business reported sales of ₹29,845 million, a growth of 20.3%, driven by new launches and volume increases. The company filed 192 ANDAs, 2 NDAs, and 1 BLA with the USFDA as of March 31, 2026, and received approvals for 167 ANDAs and 2 NDAs. The board fixed August 7, 2026, as the record date for the payment of the final dividend, with the 52nd Annual General Meeting scheduled for August 27, 2026. The auditors, Deloitte Haskins & Sells LLP, issued an unmodified opinion on the financial results.

Pipeline and Product Updates

Alkem Labs anticipates the U.S. launch of Tolvaptan by September or October, targeting the second half of the fiscal year in a market characterised by limited competition. On the domestic front, the company launched Semaglutide injectables in March 2026, achieving an 11% market share, with expectations for further growth. Clinical trials for Semaglutide tablets are currently underway, with the company aiming for regulatory approval and a defined market release strategy. Additionally, Alkem Labs plans to transition to the new tax regime by April 2026, revising its tax rate guidance downward to 27%-29% from the earlier range of 35%-38%.

FY27 Outlook

Looking ahead, Alkem Labs expects strong growth across its key markets. The company anticipates high-single-digit growth in the US market, with additional gains expected from currency tailwinds and new product launches. Rest of World (ROW) markets are anticipated to deliver high-teens growth. For FY27, the EBITDA margin is projected to be in the range of 20% to 21%, subject to geopolitical factors and cost clarity. On the domestic front, Alkem Labs aims for business growth to be 1 to 1.5 percentage points higher than the market, indicating double-digit growth, with Semaglutide identified as a key driver for sustaining momentum.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE540L01014/79e16f1f0bb84b2b.pdf